W
omen's health encompasses a broad range of issues unique to the female patient, with a scope that has expanded beyond reproductive health. Providers who care for women must develop cross-disciplinary competencies and understand the complex role of sex and gender on disease expression and treatment outcomes. Staying current with the literature in this rapidly changing fi eld can be challenging for the busy clinician.
This article reviews recent advances in the treatment of depression in pregnancy, nonhormonal therapies for menopausal symptoms, and heart failure therapy in women, highlighting notable studies published in 2014 and early 2015.
■ TREATMENT OF DEPRESSION IN PREGNANCY A 32-year-old woman with well-controlled but recurrent depression presents to the clinic for preconception counseling. Her depression has been successfully managed with a selective serotonin reuptake inhibitor (SSRI). She and her husband would like to try to conceive soon, but she is worried that continuing on her current SSRI may harm her baby. How should you advise her?
tract obstruction 4, 5 and have linked sertraline to ventricular septal defects. 6 However, reports of associations of congenital malformations and SSRI use in pregnancy in observational studies have been questioned, with concern that these studies had low statistical power, self-reported data leading to recall bias, and limited assessment for confounding factors. 3, 7 Recent studies refute risk of cardiac malformations Several newer studies have been published that further examine the association between SSRI use in pregnancy and congenital heart defects, and their fi ndings suggest that once adjusted for confounding variables, SSRI use in pregnancy may not be associated with cardiac malformations.
Huybrechts et al, 8 in a large study published in 2014, extracted data on 950,000 pregnant women from the Medicaid database over a 7-year period and examined it for SSRI use during the fi rst 90 days of pregnancy. Though SSRI use was associated with cardiac malformations when unadjusted for confounding variables (unadjusted relative risk 1.25, 95% confi dence interval [CI] 1.13-1.38), once the cohort was restricted to women with a diagnosis of only depression and was adjusted based on propensity scoring, the association was no longer statistically signifi cant (adjusted relative risk 1.06, 95% CI 0.93-1.22).
Additionally, there was no association between sertraline and ventricular septal defects (63 cases in 14,040 women exposed to sertraline, adjusted relative risk 1.04, 95% CI 0.76-1.41), or between paroxetine and right ventricular outfl ow tract obstruction (93 cases in 11,126 women exposed to paroxetine, adjusted relative risk 1.07, 95% CI 0.59-1.93). 8 
Furu et al
7 conducted a sibling-matched case-control comparison published in 2015, in which more than 2 million live births from fi ve Nordic countries were examined in the full cohort study and 2,288 births in the sibling-matched case-control cohort. SSRI or venlafaxine use in the fi rst 90 days of pregnancy was examined. There was a slightly higher rate of cardiac defects in infants born to SSRI or venlafaxine recipients in the cohort study (adjusted odds ratio 1.15, 95% CI 1.05-1.26).
However, in the sibling-controlled analyses, neither an SSRI nor venlafaxine was associated with heart defects (adjusted odds ratio 0.92, 95% CI 0.72-1.17), leading the authors to conclude that there might be familial factors or other lifestyle factors that were not taken into consideration and that could have confounded the cohort results.
Bérard et al 9 examined antidepressant use in the fi rst trimester of pregnancy in a cohort of women in Canada and concluded that sertraline was associated with congenital atrial and ventricular defects (risk ratio 1.34; 95% CI 1.02-1.76). 9 However, this association should be interpreted with caution, as the Canadian cohort was notably smaller than those in other studies we have discussed, with only 18,493 pregnancies in the total cohort, and this conclusion was drawn from 9 cases of ventricular or atrial septal defects in babies of 366 women exposed to sertraline.
Although at fi rst glance SSRIs may appear to be associated with congenital heart defects, these recent studies are reassuring and suggest that the association may actually not be significant. As with any statistical analysis, thoughtful study design, adequate statistical power, and adjustment for confounding factors must be considered before drawing conclusions.
SSRIs, offspring psychiatric outcomes, and miscarriage rates Clements et al 10 studied a cohort extracted from Partners Healthcare consisting of newborns with autism spectrum disorder, newborns with attention-defi cit hyperactivity disorder (ADHD), and healthy matched controls and found that SSRI use during pregnancy was not associated with offspring autism spectrum disorder (adjusted odds ratio 1.10, 95% CI 0.7-1.70). However, they did fi nd an increased risk of ADHD with SSRI use during pregnancy (adjusted odds ratio 1.81, 95% CI 1.22-2.70).
Andersen et al 11 examined more than 1 million pregnancies in Denmark and found no difference in risk of miscarriage between women who used an SSRI during pregnancy (adjusted hazard ratio 1.27) and women who discontinued their SSRI at least 3 months before pregnancy (adjusted hazard ratio 1.24, P = .47). The authors concluded that because of SSRI use during pregnancy has drawn attention due to mixed reports of teratogenic effects KRANSDORF AND COLLEAGUES the similar rate of miscarriage in both groups, there was no association between SSRI use and miscarriage, and that the small increased risk of miscarriage in both groups could have been attributable to a confounding factor that was not measured.
Should our patient continue her SSRI through pregnancy?
Our patient has recurrent depression, and her risk of relapse with antidepressant cessation is high. Though previous, less well-done studies suggested a small risk of congenital heart defects, recent larger high-quality studies provide signifi cant reassurance that SSRI use in pregnancy is not strongly associated with cardiac malformations. Recent studies also show no association with miscarriage or autism spectrum disorder, though there may be risk of offspring ADHD.
She can be counseled that she may continue on her SSRI during pregnancy and can be reassured that the risk to her baby is small compared with her risk of recurrent or postpartum depression. Paroxetine 7.5 mg is approved for vasomotor symptoms of menopause As many as 75% of menopausal women in the United States experience vasomotor symptoms related to menopause, or hot fl ashes and night sweats. 12 These symptoms can disrupt sleep and negatively affect quality of life. Though previously thought to occur during a short and self-limited time period, a recently published large observational study reported the median duration of vasomotor symptoms was 7.4 years, and in African American women in the cohort the median duration of vasomotor symptoms was 10.1 years-an entire decade of life. 13 In 2013, the US Food and Drug Administration (FDA) approved paroxetine 7.5 mg daily for treating moderate to severe hot fl ashes associated with menopause. It is the only approved nonhormonal treatment for vasomotor symptoms; the only other approved treatments are estrogen therapy for women who have had a hysterectomy and combination estrogen-progesterone therapy for women who have not had a hysterectomy.
■ NONHORMONAL TREATMENT FOR VASOMOTOR SYMPTOMS OF MENOPAUSE
Further studies of paroxetine for menopausal symptoms Since its approval, further studies have been published supporting the use of paroxetine 7.5 mg in treating symptoms of menopause. In addition to reducing hot fl ashes, this treatment also improves sleep disturbance in women with menopause. 14 14 in a pooled analysis of the data from the phase 3 clinical trials of paroxetine 7.5 mg per day, found that participants in groups assigned to paroxetine reported a 62% reduction in nighttime awakenings due to hot fl ashes compared with a 43% reduction in the placebo group (P < .001). Those who took paroxetine also reported a statistically signifi cantly greater increase in duration of sleep than those who took placebo (37 minutes in the treatment group vs 27 minutes in the placebo group, P = .03).
Pinkerton et al,
Some patients are hesitant to take an SSRI because of concerns about adverse effects when used for psychiatric conditions. However, the dose of paroxetine that was studied and approved for vasomotor symptoms is lower than doses used for psychiatric indications and does not appear to be associated with these adverse effects.
Portman et al 15 in 2014 examined the effect of paroxetine 7.5 mg vs placebo on weight gain and sexual function in women with vasomotor symptoms of menopause and found no signifi cant increase in weight or decrease in sexual function at 24 weeks of use. Participants were weighed during study visits, and those in the paroxetine group gained on average 0.48% from baseline at 24 weeks, compared with 0.09% in the placebo group (P = .29).
Sexual dysfunction was assessed using the Arizona Sexual Experience Scale, which has been validated in psychiatric patients using antidepressants, and there was no signifi cant
The median duration of menopausal vasomotor symptoms overall was 7.4 years, and 10.1 years in African Americans difference in symptoms such as sex drive, sexual arousal, vaginal lubrication, or ability to achieve orgasm between the treatment group and placebo group. 15 Of note, paroxetine is a potent inhibitor of the cytochrome P-450 CYP2D6 enzyme, and concurrent use of paroxetine with tamoxifen decreases tamoxifen activity. 12, 16 Since women with a history of breast cancer who cannot use estrogen for hot fl ashes may be seeking nonhormonal treatment for their vasomotor symptoms, providers should perform careful medication reconciliation and be aware that concomitant use of paroxetine and tamoxifen is not recommended.
Other antidepressants show promise but are not approved for menopausal symptoms
In addition to paroxetine, other nonhormonal drugs have been studied for treating hot fl ashes, but they have been unable to secure FDA approval for this indication. One of these is the serotonin-norepinephrine reuptake inhibitor venlafaxine, and a 2014 study 17 confi rmed its effi cacy in treating menopausal vasomotor symptoms.
Joffe et al 17 performed a three-armed trial comparing venlafaxine 75 mg/day, estradiol 0.5 mg/day, and placebo and found that both of the active treatments were better than placebo at reducing vasomotor symptoms. Compared with each other, estradiol 0.5 mg/day reduced hot fl ash frequency by an additional 0.6 events per day compared with venlafaxine 75 mg/day (P = .09). Though this difference was statistically signifi cant, the authors pointed out that the clinical signifi cance of such a small absolute difference is questionable. Additionally, providers should be aware that venlafaxine has little or no effect on the metabolism of tamoxifen. 16 Shams et al, 18 in a meta-analysis published in 2014, concluded that SSRIs as a class are more effective than placebo in treating hot fl ashes, supporting their widespread off-label use for this purpose. Their analysis examined the results of 11 studies, which included more than 2,000 patients in total, and found that compared with placebo, SSRI use was associated with a signifi cant decrease in hot fl ashes (mean difference -0.93 events per day, 95% CI -1.49 to -0.37). A mixed treatment comparison analysis was also performed to try to model performance of individual SSRIs based on the pooled data, and the model suggests that escitalopram may be the most effi cacious SSRI at reducing hot fl ash severity.
These studies support the effectiveness of SSRIs 18 and venlafaxine 17 in reducing hot fl ashes compared with placebo, though providers should be aware that they are still not FDA-approved for this indication.
Nonhormonal therapy for our patient
We would recommend paroxetine 7.5 mg nightly to this patient, as it is an FDA-approved nonhormonal medication that has been shown to help patients with vasomotor symptoms of menopause as well as sleep disturbance, without sexual side effects or weight gain. If the patient cannot tolerate paroxetine, off-label use of another SSRI or venlafaxine is supported by the recent literature. Which patients are candidates for cardiac resynchronization therapy? Heart disease continues to be the number one cause of death in the United States for both men and women, and almost the same number of women and men die from heart disease every year. 19 Though coronary artery disease accounts for most cases of cardiovascular disease in the United States, heart failure is a significant and growing contributor. Approximately 6.6 million adults had heart failure in 2010 in the United States, and an additional 3 million are projected to have heart failure by 2030.
■ HEART DISEASE IN WOMEN: CARDIAC RESYNCHRONIZATION THERAPY
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The burden of disease on our health system is high, with about 1 million hospitalizations and more than 3 million outpatient offi ce visits attributable to heart failure yearly. 20 Patients with heart failure may have symptoms of dyspnea, fatigue, orthopnea, and periph eral edema; laboratory and radiologic fi ndings of pulmonary edema, renal insufficiency, and hyponatremia; and electrocardiographic fi ndings of atrial fi brillation or prolonged QRS. 21 Intraventricular conduction delay (QRS duration > 120 ms) is associated with dyssynchronous ventricular contraction and impaired pump function and is present in almost one-third of patients who have advanced heart failure. 21 Cardiac resynchronization therapy, or biventricular pacing, can improve symptoms and pump function and has been shown to decrease rates of hospitalization and death in these patients. 22 According to the joint 2012 guidelines of the American College of Cardiology Foundation, American Heart Association, and Heart Rhythm Society, 22 it is indicated for patients with an ejection fraction of 35% or less, left bundle-branch block with QRS duration of 150 ms or more, and NYHA class II to IV symptoms who are in sinus rhythm (class I recommendation, level of evidence A).
Studies of cardiac resynchronization therapy in women
Recently published studies have suggested that women may derive greater benefi t than men from cardiac resynchronization therapy.
Zusterzeel et al 23 (2014) evaluated sexspecifi c data from the National Cardiovascular Data Registry, which contains data on all biventricular pacemaker and implantable cardioverter-defi brillator implantations from 80% of US hospitals. 23 Of the 21,152 patients who had left bundle-branch block and received cardiac resynchronization therapy, women derived greater benefi t in terms of death than men did, with a 21% lower risk of death than men (adjusted hazard ratio 0.79, 95% CI 0.74-0.84, P < .001). This study was also notable in that 36% of the patients were women, whereas in most earlier studies of cardiac resynchronization therapy women accounted for only 22% to 30% of the study population. 22 24 (2014) performed a follow-up analysis of the Multicenter Automatic Defi brillator Implantation Trial With Cardiac Resynchronization Therapy. Subgroup analysis showed that although both men and women had a lower risk of death if they received cardiac resynchronization therapy compared with an implantable cardioverter-defi brillator only, the magnitude of benefi t may be greater for women (hazard ratio 0.48, 95% CI 0.25-0.91, P = .03) than for men (hazard ratio 0.69, 95% CI 0.50-0.95, P = .02).
Goldenberg et al
In addition to deriving greater mortality benefi t, women may actually benefi t from cardiac resynchronization therapy at shorter QRS durations than what is currently recommended. Women have a shorter baseline QRS than men, and a smaller left ventricular cavity. 25 In an FDA meta-analysis published in August 2014, pooled data from more than 4,000 patients in three studies suggested that women with left bundlebranch block benefi ted from cardiac resynchronization therapy more than men with left bundle-branch block. 26 Neither men nor women with left bundle-branch block benefi ted from it if their QRS duration was less than 130 ms, and both sexes benefi ted from it if they had left bundle-branch block and a QRS duration longer than 150 ms. However, women who received it who had left bundle-branch block and a QRS duration of 130 to 149 ms had a signifi cant 76% reduction in the primary composite outcome of a heart failure event or death (hazard ratio 0.24, 95% CI 0.11-0.53, P < .001), while men in the same group did not derive signifi cant benefi t (hazard ratio 0.85, 95% CI 0.60-1.21, P = .38).
Despite the increasing evidence that there are sex-specifi c differences in the benefi t from cardiac resynchronization therapy, what we know is limited by the low rates of female enrollment in most of the studies of this treatment. In a systematic review published in 2015, Herz et al 27 found that 90% of the 183 studies they reviewed enrolled 35% women or less, and half of the studies enrolled less than 23% women. Furthermore, only 20 of the 183 studies reported baseline characteristics by sex.
Recognizing this lack of adequate data, in August 2014 the FDA issued an offi cial guidance statement outlining its expectations regarding sex-specifi c patient recruitment, data analysis, and data reporting in future medical Heart disease continues to be the number one cause of death in both men and women device studies. 28 Hopefully, with this support for sex-specifi c research by the FDA, future studies will be able to identify therapeutic outcome differences that may exist between male and female patients.
Should our patient receive cardiac resynchronization therapy?
Regarding our patient with heart failure, the above studies suggest she will likely have a lower risk of death if she receives cardiac resynchronization therapy, even though her QRS interval is shorter than 150 ms. Providers who are aware of the emerging data regarding sex differences and treatment response can be powerful advocates for their patients, even in subspecialty areas, as highlighted by this case. We recommend counseling this patient to proceed with cardiac resynchronization therapy.
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